Why Iovance Biotherapeutics Inc (IOVA) Stock Is Rising
As of 2026-09-29, Iovance Biotherapeutics Inc (IOVA) has a next-year EPS growth estimate of 53.27%. Featured in our EPS revision report on 2026-09-29.
Why IOVA Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Iovance Biotherapeutics Inc's next-year EPS growth estimate from 51.49% to 52.03% on 2026-09-24.
- →Estimate Trending Higher: Since detection, the estimate has moved up a net +1.24 pp to 53.27% across 1 upward revision.
- ·Current-Year Growth: Projected at 58.68%, supporting the forward estimate revision.
News Context
The primary structural driver is the 2026-09-24 analyst upgrade to Iovance’s next-year EPS growth estimate, from 51.49% to 52.03%, with a net EPS change of +1.24 pp and a current estimate of 53.27%. That revision plausibly connects to the company’s raised FY2026 revenue
Generated 2026-09-29 · news as of 2026-09-29
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 53.27%
- EPS growth this year
- 58.68%
- EPS next quarter (est)
- -$0.09
- Last price
- $14.45
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-09-29 | 53.27% | 58.68% | -$0.09 | $14.45 |
| 2026-09-28 | 52.03% | 56.34% | -$0.09 | $10.99 |
| 2026-09-27 | 52.03% | 56.34% | -$0.09 | $11.00 |
| 2026-09-25 | 52.03% | 56.34% | -$0.09 | $11.00 |
| 2026-09-24 | 52.03% | 56.34% | -$0.09 | $10.80 |
| 2026-09-23 | 51.49% | 55.93% | -$0.09 | $10.19 |
| 2026-09-22 | 51.49% | 55.93% | -$0.09 | $10.64 |
| 2026-09-21 | 51.49% | 55.93% | -$0.09 | $10.19 |
| 2026-09-20 | 51.49% | 55.93% | -$0.09 | $10.25 |
| 2026-09-18 | 51.49% | 55.93% | -$0.09 | $10.25 |
| 2026-09-17 | 51.49% | 55.93% | -$0.09 | $10.02 |
| 2026-09-16 | 48.75% | 55.81% | -$0.09 | $9.87 |
| 2026-09-15 | 48.75% | 55.81% | -$0.09 | $9.36 |
| 2026-09-14 | 48.75% | 55.81% | -$0.09 | $9.26 |
| 2026-09-13 | 48.75% | 55.81% | -$0.09 | $8.60 |
| 2026-09-11 | 48.75% | 55.81% | -$0.09 | $8.60 |
| 2026-09-10 | 48.75% | 55.81% | -$0.09 | $8.14 |
| 2026-09-09 | 48.75% | 55.81% | -$0.09 | $8.43 |
| 2026-09-08 | 48.75% | 55.81% | -$0.09 | $8.70 |
| 2026-09-07 | 48.75% | 55.81% | -$0.09 | $8.79 |
| 2026-09-06 | 48.75% | 55.81% | -$0.09 | $8.79 |
| 2026-09-04 | 48.75% | 55.81% | -$0.09 | $8.79 |
| 2026-09-03 | 48.75% | 55.81% | -$0.09 | $8.70 |
| 2026-09-02 | 48.75% | 55.81% | -$0.09 | $8.62 |
| 2026-09-01 | 48.75% | 55.81% | -$0.09 | $8.28 |
| 2026-08-31 | 48.75% | 55.81% | -$0.09 | $8.17 |
| 2026-08-30 | 48.75% | 55.81% | -$0.09 | $8.01 |
| 2026-08-29 | 48.75% | 55.81% | -$0.09 | $8.01 |
| 2026-08-28 | 48.75% | 55.81% | -$0.09 | $8.01 |
| 2026-08-27 | 48.75% | 55.81% | -$0.09 | $8.26 |
Reports Featuring IOVA
Recent News
- Iovance Stock Surges as Strong Melanoma Drug Demand Drives GrowthBarrons.com
- IOVA Stock Hits Over 2-Year Highs Why Iovance Raised Its FY2026 Revenue OutlookStocktwits
- Iovance Raises 2026 Revenue Guidance to $410 Million-$420 MillionInvestorsHub
- Iovance shares jump in premarket as raised outlook clears consensus viewsInvesting.com
- Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 MillionGlobeNewswire
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Why Did CRWD, OKTA, IOVA Shares Climb To 52-Week Highs Today?Stocktwits
- IOVA Stock Has Gained More Than 21% In Four Sessions, And Barclays Sees Another 52% Upside Potential - Heres WhyStocktwits
- IOVA Stock Has Gained More Than 21% In Four Sessions, And Barclays Sees Another 52% Upside Potential - Heres WhyStocktwits
- This Tiny Biotech Is Beating MRNA, IOVA And SLS Here's How A Billionaire Fueled Its September RallyStocktwits
Screen Performance
Aggregate stats across all 2057 tickers our top-EPS-revision screen has flagged over the past 181 days.
- Median return since detection
- +0.0%
- % of tickers in the green
- 48%
- Median return on winners
- +23.5%
- Large revisions captured
- 1786
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Iovance Biotherapeutics Inc (IOVA) stock go up recently?▾
Iovance Biotherapeutics Inc (IOVA) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 51.49% to 52.03% on 2026-09-24. Since detection, the estimate has moved up a net +1.24 pp to 53.27%. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Iovance Biotherapeutics Inc's next-year EPS growth estimate?▾
As of 2026-09-29, Iovance Biotherapeutics Inc (IOVA) has a next-year EPS growth estimate of 53.27%, based on analyst consensus.
When was the latest EPS estimate revision for IOVA?▾
The most recent revision occurred on 2026-09-29, when analysts adjusted the next-year EPS growth estimate from 52.03% to 53.27%.
What sector and industry does Iovance Biotherapeutics Inc belong to?▾
Iovance Biotherapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. IOVA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Iovance Biotherapeutics Inc (IOVA) appears here because it was detected by our daily top-EPS-revision-performer screen.